Kaletra contains the antiviral agents lopinavir and ritonavir as its active components. It is a pill formulation marketed in a fixed-dose combination of 200 mg lopinavir / 50 mg ritonavir per tablet. The medication belongs to the HIV management therapeutic class and is prescribed by healthcare professionals to treat people living with human immunodeficiency virus (HIV). In Hong Kong, Kaletra is classified as a prescription-only product and is regulated by the Department of Health.
Lopinavir is a protease inhibitor that blocks the HIV-1 protease enzyme, preventing the virus from cleaving its polyprotein precursors into functional viral proteins. This halts the production of mature, infectious HIV particles.
Ritonavir, while also a protease inhibitor, is primarily used at a low dose to boost lopinavir’s plasma concentrations. It does this by inhibiting the liver enzyme CYP3A4, which would otherwise metabolize lopinavir rapidly. The result is higher and more sustained levels of lopinavir, enhancing its antiviral effectiveness.
Together, the two agents provide a dual-action regimen: lopinavir directly suppresses viral replication, and ritonavir ensures adequate drug exposure. Onset of viral suppression typically begins within weeks of consistent dosing, with maximum effect observed after several months of therapy.
Kaletra is approved by major regulatory agencies (e.g., U.S. FDA, European EMA) for the treatment of HIV-1 infection in adults and adolescents aged ≥ 14 years. It is used as part of combination antiretroviral therapy (cART) together with other agents such as nucleoside reverse-transcriptase inhibitors (NRTIs).
Typical patient populations include:
In Hong Kong, the Department of Health follows World Health Organization (WHO) treatment guidelines, which list a lopinavir/ritonavir-based regimen as an acceptable first-line or second-line option depending on national formulary decisions.
During the early phases of the COVID-19 pandemic, lopinavir/ritonavir was studied as a potential antiviral treatment for SARS-CoV-2 infection. Clinical trials produced mixed results, and the regimen is not approved for COVID-19 by any regulatory agency.
Disclaimer: Off-label use of Kaletra for conditions such as COVID-19 requires close medical supervision, individualized risk assessment, and should be guided by current clinical trial evidence and local health authority recommendations.
When uncertainty exists about suitability, healthcare providers should evaluate individual health status, concomitant medications, and laboratory parameters before initiating therapy.
These effects are usually transient; supportive measures such as adequate hydration and dietary adjustments can help alleviate symptoms.
If any serious reaction is suspected, medical attention should be obtained immediately.
Major Interactions (require therapy modification or avoidance)
Moderate Interactions (require monitoring)
Mechanistic Note: Ritonavir’s inhibition of CYP3A4 is the primary basis for many pharmacokinetic interactions.
Patients should promptly report new or worsening symptoms, especially abdominal pain, jaundice, or signs of pancreatitis.
This article provides educational information about Kaletra and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Persistent diarrhea may be a common side effect, but if it continues for more than a few days or leads to dehydration, contact your healthcare provider. They may recommend dietary adjustments, antidiarrheal agents, or evaluate the need for a regimen change.
Yes, Kaletra is typically prescribed as part of a combination regimen that includes nucleoside reverse-transcriptase inhibitors (NRTIs) or integrase inhibitors. Your prescriber will select compatible agents based on resistance patterns and potential drug-drug interactions.
Traveling with Kaletra is generally safe. Carry the medication in its original packaging, keep it with you in case of luggage inspection, and maintain consistent dosing across time zones. Stay hydrated and monitor for any new side effects, especially if changing diet.
Grapefruit juice can inhibit CYP3A4, potentially increasing ritonavir and lopinavir concentrations. While moderate consumption is unlikely to cause serious problems, it is advisable to limit grapefruit intake and discuss any concern with your provider.
Both are boosted protease inhibitors, but they differ in dosing frequency, metabolic profile, and side-effect spectrum. For example, atazanavir is often taken once daily and may cause hyperbilirubinemia, whereas Kaletra requires twice-daily dosing and is more associated with gastrointestinal disturbances.
Symptoms may include dark urine, yellowing of the skin or eyes (jaundice), upper-right abdominal pain, and unusually high fatigue. Promptly seek medical evaluation if these occur.
Lopinavir/ritonavir is primarily metabolized by the liver, so mild renal impairment usually does not require dose adjustment. Nonetheless, renal function should be monitored periodically.
If viral suppression is not achieved or adherence is inconsistent, HIV can develop mutations that reduce susceptibility to lopinavir/ritonavir. Maintaining strict adherence and regular viral load monitoring helps prevent resistance.
Keep tablets in a cool, dry place away from direct sunlight. If ambient temperatures exceed recommended storage conditions, store the medication in a climate-controlled environment such as a refrigerator (do not freeze) if the label permits.
As of the latest regulatory updates, several generic lopinavir/ritonavir products are approved and listed on the Hong Kong Department of Health’s formulary. Patients should discuss availability and cost considerations with their prescriber or pharmacist.
